Cancer-associated genetic alterations induce expression of tumour antigens that can activate CD8 1 cytotoxic T cells (CTLs), but the microenvironment of established tumours promotes immune tolerance through poorly understood mechanisms 1, 2 . Recently developed therapeutics that overcome tolerogenic mechanisms activate tumour-directed CTLs and are effective in some human cancers 1 . Immune mechanisms also affect treatment outcome, and certain chemotherapeutic drugs stimulate cancer-specific immune responses by inducing immunogenic cell death and other effector mechanisms 3, 4 . Our previous studies revealed that B cells recruited by the chemokine CXCL13 into prostate cancer tumours promote the progression of castrate-resistant prostate cancer by producing lymphotoxin, which activates an IkB kinase a (IKKa)-BMI1 module in prostate cancer stem cells 5, 6 . Because castrate-resistant prostate cancer is refractory to most therapies, we examined B cell involvement in the acquisition of chemotherapy resistance. Here we focus on oxaliplatin, an immunogenic chemotherapeutic agent 3, 4 that is effective in aggressive prostate cancer 7 . We show that mouse B cells modulate the response to low-dose oxaliplatin, which promotes tumour-directed CTL activation by inducing immunogenic cell death. Three different mouse prostate cancer models were refractory to oxaliplatin unless genetically or pharmacologically depleted of B cells. The crucial immunosuppressive B cells are plasmocytes that express IgA, interleukin (IL)-10 and programmed death ligand 1 (PD-L1), the appearance of which depends on TGFb receptor signalling. Elimination of these cells, which also infiltrate human-therapy-resistant prostate cancer, allows CTL-dependent eradication of oxaliplatin-treated tumours.
Using the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) model of metastatic prostate cancer (PC) 8 , we examined how lymphocytes affect the response to low-dose oxaliplatin. Although early (#0.2 g) tumours responded to oxaliplatin regardless of B cell status (Extended Data Fig. 1a, b) , after reaching $0.7 g, wild-type tumours became largely resistant to 'late' chemotherapy ( Fig. 1a ). However, tumours arising in B-cell-deficient TRAMP;Jh 2/2 hybrid mice were oxaliplatin sensitive ( Fig. 1a ), although B cells had little effect on tumour progression and histology (Extended Data Fig. 1c, d) . CD8 1 -cell-deficient TRAMP;Cd8a 2/2 mice bearing small tumours were less responsive to oxaliplatin, but large tumours were treatment-resistant ( Fig. 1a and Extended Data Fig. 1b ). Similar results were obtained by subcutaneous transplantation of mouse Myc-CaP (MC) prostate cancer cells 9 . Whereas small MC tumours (#100 mm 3 ) were chemotherapy responsive in wild-type mice (Extended Data Fig. 1e , f), large MC tumours ($350-400 mm 3 ) shrank after oxaliplatin treatment only in Jh 2/2 (also known as Igh-J 2/2 ) mice ( Fig. 1b-d) . No response was observed in Cd8a 2/2 mice. Oxaliplatin responsiveness was associated with enhanced caspase 3 activation, but the tumoral DNA damage response measured by histone H2AX phosphorylation was similarly activated by oxaliplatin, regardless of the host genotype ( Fig. 1e and Extended Data Fig. 1g -i). Oxaliplatin treatment increased tumour-infiltrating CD45 1 cells in wild-type and Jh 2/2 mice, but myofibroblast activation and CD31 infiltration was more pronounced in wild-type mice (Extended Data Fig. 1j-l ). Low-dose oxaliplatin enhanced TRAMP mouse survival in a manner dependent on CTLs and inhibitable by B cells (Extended Data Fig. 1m, n) . B cell immunodepletion also enhanced oxaliplatin-induced tumour regression and the effect was CTL-dependent ( Fig. 1f ).
Oxaliplatin stimulated CD8 1 cell recruitment in TRAMP and TRAMP;Jh 2/2 mice, although more tumoral CD8 1 cells were found in the latter ( Fig. 2a and Extended Data Fig. 2a) . B cell deficiency also enhanced oxaliplatin-induced CD8 1 and CD4 1 cell recruitment into MC tumours and induction of perforin, interferon-c (IFNc) and tumour necrosis factor (TNF) in CD8 1 cells (Fig. 2b-e and Extended Data Fig. 2b-e ). MC tumours in Jh 2/2 mice contained more CD8 1 cells with activated STAT1, more proliferative CD8a 1 CD44 hi GrzB 1 Ki67 1 cells and fewer 'exhausted' 2 CD8a 1 CD44 1 PD-1 1 Tim-3 1 and CD8 1 BTLA hi cells, the presence of which in wild-type tumours was increased by oxaliplatin ( Fig. 2f-h and Extended Data Fig. 2f-i) . B cell immunodepletion also enhanced tumoral CTL activation (Extended Data Fig. 2j-p) .
Oxaliplatin treatment greatly increased the number of tumoral B220 1 CD19 1 B cells ( Fig. 3a and Extended Data Fig. 3a, b ). After 3-4 treatment cycles, at least 40% of tumoral B cells were CD20 2/low CD19 1 B220 low CD138 1 plasma cells, 40-80% of which expressed IgA (Fig. 3b , c and Extended Data Fig. 3c -l). IgA 1 B cells became detectable 48 h after the first treatment cycle, and their abundance increased to nearly 80% of B220 low cells after additional cycles (Extended Data Fig. 3g, l) . When cultured ex vivo, tumoral IgA 1 B cells released soluble IgA (Extended Data Fig. 4a ). Oxaliplatin also increased serum IgA in both TRAMP and MC-tumour models, but had little effect on serum IgG (Extended Data Fig. 4b-e ). Plasmocytic IgA 1 cells were found adjacent to a-smooth muscle actin (aSMA)-expressing myofibroblasts (Fig. 3d ), which produce CXCL13 (ref. 10 ). Oxaliplatin-induced IgA 1 B cells from spleen and MC tumours expressed activation-induced cytidine deaminase (Extended Data Fig. 4f, g ), suggesting recent class-switch recombination (CSR).
The IgA CSR is mainly induced by TGFb together with CD40L, IL-21, IL-10 or IL-6 (ref. 11 ). Indeed, oxaliplatin increased the proportion of tumoral B cells containing phosphorylated SMAD2/3, and induced Tgfb1 messenger RNA in tumours ( Fig. 4j ). However, lymphotoxin a/b (LTa/b)-producing B cells did not express IL-10 and their abundance was barely increased by oxaliplatin (Extended Data Fig. 4o , p). Tumoral CD19 1 cells did not express CD5, a B regulatory (B reg ) cell marker 12 (Extended Data Fig. 4q ). Oxaliplatin induced other immunoregulatory molecules, including NOS2, ARG1, IL-12p35 and IL-12p40, but no differences were observed between tumour-bearing wild-type and Jh 2/2 mice, although the latter expressed higher amounts of IL-12 (Extended Data Fig. 5a-d) . B cell deficiency or depletion had no significant effect on tumoral natural killer cells, myeloid CD11b 1 Gr1 1 cells, macrophages or T reg cells (Extended Data Fig. 5e -i). Thus, unlike mouse skin cancer, in which B cells modulate therapeutic responsiveness through macrophages 13 , B cells in mouse PC impede immunogenic chemotherapy by suppressing CTL activation.
Human PC samples (n 5 110) were analysed for CD8 1 and CD20 1 cells (Extended Data Fig. 6a, b ). Comparison of matched normal and tumour tissues from 87 patients with early-stage PC (E-PC) indicated higher CD8 1 and CD20 1 counts in tumours (Extended Data Fig. 6c, d) . Patients with therapy-resistant PC (TR-PC) or metastatic PC (M-PC) exhibited reduced tumoral CD8 1 cell density relative to patients with E-PC, the tumours of which contained fewer B cells than TR-PC and M-PC, in which B cells were most abundant (Extended Data Fig. 6e, f ). E-PC specimens displayed higher CD8/CD20 ratios than specimens from TR-PC and M-PC (Extended Data Fig. 6g ). Immunofluorescence and immunohistochemical analyses of human PC specimens revealed IgA 1 cells in a scattered formation, frequently next to aSMA 1 myofibroblasts, especially in the high-risk group ( Fig. 3l and Extended Data Fig. 6h -j, n). CD20 1 B cells were both scattered and clustered in lymphoid follicle-like 10 areas (Extended Data Fig. 6b , k). Human PC also contained IL-10-producing IgA 1 CD138 1 cells and some IgA 1 cells were adjacent to CD8 1 T cells and expressed little CD20 (Extended Data Fig. 6i -k). 25% of IgA 1 cells in fresh prostatectomy specimens expressed IL-10 and were enriched in the malignant tissue portion (Extended Data Fig. 6l , m). IgA 1 CD138 1 plasmocytes exhibited higher density in TR-PC and M-PC than E-PC and patients with higher IgA 1 CD138 1 cell counts showed lower CD8/CD20 ratios (Extended Data Fig. 6n-p ). Oncomine analysis of human IgA (IGHA1) mRNA revealed increased levels in malignant versus healthy prostates in 11 out of 15 data sets. Of these, five showed (FVB) mice (wild-type (TR-WT), TR-Jh 2/2 and TR-Cd8a 2/2 ; n 5 7-15 per group) received weekly oxaliplatin (6 mg kg 21 ), starting at week 16. After 4 weeks, prostate weights were measured. Dashed red line denotes prostate weight of naive controls. b, Tumour growth in mice transplanted with MC cells and treated with oxaliplatin, as in Extended Data Fig. 1e (late treatment), or 5% dextrose (n 5 4-9 per group). c, Weights of MC tumours after oxaliplatin or vehicle treatment (n 5 5-7 per group). d, Mice of indicated genotypes bearing MC tumours (n 5 7-11 per group) were treated as above. After three cycles, tumour volumes (mm 3 ) were determined. e, Numbers of cleaved caspase 3 (CC3) CD45 2 cells per high-magnification field (HMF; 3200) in tumours from Extended Data Fig. 1g . f, MC tumours were inoculated into wild-type (left) or Cd8a 2/2 (right) mice. After 16 days, B cells were depleted with antibodies against CD19, CD20, CD22 and B220. Four days after first twiceweekly antibody treatment, mice received weekly oxaliplatin (n 5 4-7 per group, total: 42), and euthanized 3 weeks later. Results are mean 6 s.e.m. Tumour volumes were first analysed by Kruskal-Wallis test comparing all groups: **P 5 0.007. Mann-Whitney and t-tests were used to determine significance between two groups indicated, as *P , 0.05; **P , 0.01; ***P , 0.001. The number of mice and replications for each experiment are also shown in Supplementary Table 1 . NS, not significant. LETTER RESEARCH a significant increase (P , 0.05) and three showed a .twofold change. Results of one analysis 14 are presented (Extended Data Fig. 6q ) and fit earlier findings in mice 5, 6, 15 , suggesting that tumour infiltrating lymphocytes also control malignant progression and response to therapy in human PC.
Consistent with previous knowledge 11 and SMAD2/3 activation in PD-L1 1 cells, TGFbR2 ablation in B cells (Tgfbr2 DB ) enhanced oxaliplatin-induced tumour regression, mildly decreased tumour-infiltrating, but not splenic, B cells, and inhibited oxaliplatin-induced IgA 1 plasmocyte generation without affecting IgG1 1 or IgG2a 1 cells ( Fig. 4a-d and Extended Data Fig. 7a-e ). IgA ablation also potentiated oxaliplatin responsiveness without reducing tumoral B cells ( Fig. 4a, b ). Both TGFbR2 and IgA ablations prevented induction of tumoral PD-L1 1 or IgA 1 IL-10 1 B cells by oxaliplatin, but barely affected IL-10 in B220 hi IgA 2 B cells (Extended Data Fig. 7f , g). TGFbR2 ablation or IgA deficiency also increased tumoral CTL density, IFNc production and surface CD107a expression by CD8 1 T cells of oxaliplatin-treated mice ( Fig. 4e, f ). Suppressor B cells may attenuate T cell activation via PD-L1 (ref. 16 ). Treatment of mice bearing MC tumours with oxaliplatin plus anti-PD-L1, but not anti-PD-L1 alone, inhibited tumour growth, increased GrzB expression by effector T cells, downregulated PD-L1 expression on IgA 1 cells, and reduced serum IgA, but not IgG (Extended Data Fig. 7h -m). Reconstitution of tumour-bearing Jh 2/2 hosts with B cells lacking either PD-L1 or IL-10 failed to inhibit oxaliplatin-induced tumour regression ( Fig. 4g and Extended Data Fig. 7n -p). PD-L1 ablation did not affect IL-10 expression, and IL-10 ablation had no effect on PD-L1 (Extended Data Fig. 10m , n), indicating that both molecules are needed for plasmocyte-mediated immunosuppression.
We used oxaliplatin because of its well-described immunogenic properties, which are not exhibited by the related compound cisplatin 3, 4 . Both oxaliplatin and cisplatin induced apoptotic cell death but oxaliplatin was better in stimulating autophagy (Extended Data Fig. 8a , b). Importantly, only low-dose oxaliplatin induced regression of MC tumours in Jh 2/2 mice, whereas low-dose cisplatin was ineffective, and only oxaliplatin increased the abundance of tumoral CD8 1 and CD4 1 cells (Extended Data Fig. 8c-e ). Low-dose oxaliplatin did not increase intestinal permeability and had no effect on IgA production and other immune parameters in tumour-free wild-type or Tgfbr2 DB mice (Extended Data Fig. 8f -k).
Immunogenic chemotherapy also potentiates the effectiveness of adoptively transferred T cells (ATCT). Immunogenic TRAMP-C2 cells 17 were inoculated into B-cell-containing Tcrb 2/2 mice followed by oxaliplatin treatment and ATCT (Extended Data Fig. 9a ). Bigger tumours in Tcrb 2/2 relative to wild-type mice confirmed TRAMP-C2 immunogenicity (Extended Data Fig. 9b ). However, despite successful T cell take and increased CD8 1 counts after oxaliplatin treatment, tumours were not rejected (Extended Data Fig. 9c-e ). TRAMP-C2 tumours were also raised in Rag1 2/2 ;OT-1 mice, which lack B cells and polyclonal T cells but contain CD8 1 cells directed against chicken ovalbumin (Ova) 18 . Adoptively transferred CD8 1 cells expanded and expressed GrzB in Rag1 2/2 ;OT-1 hosts, especially after oxaliplatin treatment (Extended Data Fig. 9f -h). Consequently, tumour growth was inhibited by ATCT combined with oxaliplatin (Extended Data Fig. 9i , j). More notable results were obtained in TRAMP;Rag1 2/2 mice transplanted with CFSE-labelled splenocytes from either naive wild-type (B and T cell transfer) or Jh 2/2 (T cell transfer) mice (Extended Data Fig. 9k ). CD8 1 cell proliferation in bone marrow, spleens and prostates of transplanted mice indicated successful T cell take (Extended Data Fig. 9l , m). Thirty days after lymphocyte transfer, prostate tumours were analysed. Oxaliplatin caused modest tumour shrinkage in mice receiving T and B cells, but in mice receiving only T cells it induced complete regression ( Fig. 5a, b ). Transplantation with T and B cells combined with oxaliplatin restored CD19 1 cells in spleen and prostate and serum IgA and IgG, including IgA and IgG directed against SV40 T antigen, the TRAMP oncogene ( Fig. 5c -e and Extended Data Fig. 9n ), indicating a tumour-specific humoral response. Transferred B cells expressed TIM-1 (Extended Data Fig. 9o ), a molecule involved in regulation of IL-10 expression and tolerance induction 19 . B and T cell co-transplantation led to the appearance of One day after the first treatment, CFSE-labelled splenocytes from wild-type or Jh 2/2 mice were adoptively transferred into tumour-bearing mice (n 5 4-5 per group). After three more oxaliplatin cycles, the prostates were photographed (a) and tumour weight was measured (b). c, Serum IgA in both adoptive cell transfer (ACT) groups and FVB wild-type mice. d, e, Serum anti-SV40-Tag IgA and IgG concentrations in indicated strains with or without ACT and/or oxaliplatin treatment. f, Frequency of CD8 1 cells amongst CD45 1 cells in TRAMP;Rag1 2/2 prostates after ACT and oxaliplatin treatment. g, MC tumour-bearing Rag1 2/2 mice were treated with oxaliplatin. One day later, mice (n 5 4-5 per group) received activated T cells from wild-type mice immunized with MC cell extract without or with B cells from wild-type or Tgfbr2 DB mice. After two more treatments, mice were euthanized and tumour volumes determined. h, IFNc in tumoral CD8 1 cells of above mice. Cells were re-stimulated with PMA and ionomycin before determining the percentages of IFNc-expressing cells in total CD8 1 cells (n 5 4-5 per group). i, Serum IgA in above mice. Results are mean 6 s.e.m. *P , 0.05; **P , 0.01; ***P , 0.001 (Mann-Whitney and t-tests). ND, not detectable.
LETTER RESEARCH
Our results show that successful eradication of large prostate tumours by immunogenic chemotherapy requires removal of immunosuppressive IgA 1 plasmocytes that are present both in mouse and human PC. Spontaneous and transplantable PC models contain IgA 1 plasmocytes that strongly suppress CTL activation after treatment with oxaliplatin, an immunogenic cell death inducer 4 . Although oxaliplatin causes regression of small tumours, it does not activate CTLs or shrink large prostate tumours, despite inducing DNA damage, unless tumour-infiltrating immunosuppressive B cells are removed. These B cells are IgA-producing plasmocytes that express PD-L1, IL-10 and Fas-L. Genetic analysis confirms that much of the immunosuppressive activity derives from IgA 1 PD-L1 1 IL-10 1 cells. Development of these cells, which differ from the lymphotoxin-producing CD20 1 B cells that infiltrate androgen-deprived prostate tumours and stimulate castrate-resistant prostate cancer emergence through the IKKa-BMI1 module 5, 6 , depends on TGFbR signalling. Nonetheless, CD20 1 LT 1 B cells that are exposed to high TGFb concentrations and antigen in the PC microenvironment after oxaliplatin treatment may eventually become IgA 1 plasmocytes. A likely source of TGFb is aSMA 1 myofibroblasts that reside next to IgA 1 cells in oxaliplatin-treated mouse tumours and human PC samples 10 . Alternatively, lymphotoxin-producing B cells may stimulate the IgA CSR, as signalling via LTb receptor on gut stromal cells is required for IgA production 20 . Although the anti-inflammatory and regulatory activities of intestinal IgA-producing cells 21 , as well as other plasmocytes 22 , are well known, this is the first time, to our knowledge, IgA 1 plasmocytes were found to suppress anti-tumour immunity.
IgA 1 plasmocytes within prostate tumours induce CD8 1 cell exhaustion 2 and suppress anti-tumour CTL responses through PD-L1 and IL-10, either of which can induce anergy or exhaustion 2, 23 . Yet, B cells may regulate anti-tumour immunity by other mechanisms 24, 25 , including indirect control of T cell infiltration via macrophages 13 and IL-10 production by B reg cells 26 , although the latter only affect CD4 1 T helper cells 24, 25 . Notably, IL-10-expressing IgA 1 cells are most abundant in therapy-resistant and metastatic human PC and circulating IgA is a well-established adverse prognostic indicator in PC 27 . We therefore suggest that elimination or inhibition of tumour infiltrating IgA 1 plasmocytes may be the key to successful immunotherapy of PC, as long as an immunogenic chemotherapeutic, such as oxaliplatin, is also used. Immunogenic chemotherapy may also enhance response rates to PD-1 or PD-L1 blockade in other malignancies, including bladder cancer and cutaneous melanoma in which only 35% of the patients exhibit a response 28 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Animal models. C57BL/6 and FVB control mice were from Charles River Laboratories and CD45.1 mice 29 were from the Jackson Laboratory, and all were bred at the University of California San Diego (UCSD) animal facility. C57BL/6-Tg(TRAMP)8247Ng/J (TRAMP mice) 30 were backcrossed to the FVB strain for more than ten generations. The median survival of TRAMP-FVB mice was 23 weeks compared to 52 weeks for TRAMP-C57BL/6 mice. TRAMP mice were crossed with B-cell-deficient (Jh 2/2 ) mice 31 , CTL-deficient (Cd8a 2/2 ) mice 32 or Rag1 2/2 mice, which lack both B and T cells 33 , all in the FVB-background. OT-I mice were obtained from Taconic 18 . Tgfbr2 F/F (FVB-background) mice were obtained from H. Moses 34 . Tcrb 2/2 , CD19-Cre, Il10 2/2 and CD45.1 mice were purchased from the Jackson Laboratory. IgA gene-deficient (Iga 2/2 ) mice 35 were obtained from Baylor College of Medicine. Pdl1/2 2/2 mice were obtained from Genentech. CD19-Cre and Iga 2/2 mice were backcrossed to the FVB strain for more than ten generations. All mice were maintained in filter-topped cages on autoclaved food and water at the UCSD animal facility and all experiments were performed in accordance with UCSD and NIH guidelines and regulations.
Mouse treatment studies were matched design control trials. Accordingly, mice were randomly chosen and paired based on sex (male), age and tumour size (Extended Data Fig. 1a, e ). For transplanted tumour models, tumour size was defined by the median tumour volume (for example, 400 mm 3 , for late treatments, Extended Data Fig. 1e ). For TRAMP transgenic tumour models, treatment decisions were made based on age and mice were randomly chosen including a control littermate (Extended Data Fig. 1a ). An identification code was assigned to each tumour-bearing mouse both in the transplanted and transgenic models, and the investigators were blinded to treatment allocation at the time of tumour volume measurement, autopsy and analysis. The number of mice used in each experiment and the number of experiments (replications) are shown in Supplementary Table 1 . Flow cytometry and lymphocyte isolation. For lymphocytes isolated from spleen and lymph nodes, standard protocols using filters have been used. Lymphocytes were isolated from human blood using Ficoll-Paque PLUS (GE Healthcare Life Science) according to manufacturer's recommendations. For lymphocyte isolation from tumours (mouse and human), tumours were cut into small pieces and incubated in dissociation solution (RPMI medium supplemented with 5% FBS, collagenase type I (200 U ml 21 ), collagenase type IV (200 U ml 21 ), and DNase I (100 mg ml 21 )) for 30 min at 37 uC. After incubation, cell suspensions were passed through a 50-mm cell strainer and washed twice. For large tumours ($0.7 g), haematopoietic cells were pre-enriched using density gradient centrifugation (Percoll or Ficoll). Small tumours (#0.2 g) were pooled (two tumours per staining). Red blood cells were lysed (RBC Lysis buffer, multi-species; eBioscience). For blocking of Fc-mediated interactions, mouse cells were pre-incubated with 0.5-1 mg of purified anti-mouse CD16/CD32 (93) per 100 ml and human cells were incubated with FcR blocking reagent (Miltenyi Biotec). Isolated cells were stained with labelled antibodies in PBS with 2% FCS and 2 mM EDTA or cell staining buffer (Biolegend). Dead cells were excluded based on staining with Live/Dead fixable dye (eBioscience). For intracellular cytokine staining, cells were restimulated (Myc-Cap cell lysate, PMA/ionomycin or PMA/ionomycin/LPS, as indicated) in the presence of a protein transport inhibitor cocktail containing brefeldin A and monensin (eBioscience), as indicated. For CD107, a staining antibody was added to the culture during the stimulation. After 5 h, cells were fixed and permeabilized with BD Cytofix/Cytoperm reagent for cytokine staining. BD transcription factor buffer was used for Foxp3 and T-bet staining and BD Phosflow was used for p-SMAD2/3 and p-STAT staining (BD Biosciences) according to manufacturer's recommendations. After fixation/permeabilization, cells were stained with labelled antibodies of interest. Moreover, Il10 and Actb mRNA expression were analysed on single cell level by flow cytometry in combination with CD45, IgA and IL-10 protein staining, using FlowRNA II Assay kit (Affymetrix eBioscience) according to manufacturer's protocols 36 . Cells were analysed on a Beckman Coulter Cyan ADP flow cytometer. Data were analysed using FlowJo software (Treestar). Immune cell analysis of tumour-free mice of different genetic backgrounds (C57BL/6 and FVB) and different genetic ablations are shown in Extended Data Fig. 10d -p. The gating strategies and isotype controls for p-STAT1 and IL-10 staining are shown in Extended Data Fig. 10q -u. Adoptive lymphocyte transfer. For ATCT, CD8 1 T cells were isolated from single cell suspensions, prepared from spleens and lymph nodes as described above, using CD8a-specific microbeads and MACS-columns (both Miltenyi Biotec GmbH), and 5 3 10 6 CD8 1 T cells were transferred intraperitoneally (Extended Data Fig. 9a-j) . For adoptive B cell transfer (ABCT), B cells (B220 1 / CD19 1 ) were isolated from single-cell suspensions prepared from spleens using CD19-and B220-specific microbeads and MACS-columns, and 5 3 10 6 B cells were transferred intraperitoneally ( Fig. 4g and Extended Data Fig. 7n-p) . For adoptive splenocytes transfer (ACT), single cell suspensions prepared from spleens were transferred intraperitoneally, with one total spleen injected per mouse. Labelling with 5-(and 6-) carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes) was done according to manufacturer's protocol. Five million CD8 1 T cells or 7 3 10 6 B cells were transferred (equal to one spleen per mouse; Fig. 5a-f and Extended Data Fig. 9k-r) . For combined adoptive B and T cell transfer (Fig. 5g-i and Extended Data Fig. 10a-c) , T cells were isolated from wild-type FVB mice immunized with a Myc-Cap cell lysate as previously described 37 . Specifically, Myc-Cap cells were incubated with oxaliplatin (40 mM) for 48 h. The extent of cell death was determined by flow cytometry, showing that more than 90% of cells were positive for annexin V and propidium iodide. The dead cells were injected subcutaneously into wild-type FVB mice. Seven days later, T cells were isolated from single cell suspensions of spleen and lymph nodes using a Pan T cell isolation kit (Miltenyi Biotec). B cells were isolated from spleens of naive FVB wild-type or Tgfbr2 DB mice using a Pan B cell isolation kit (Miltenyi Biotec). MC-tumour bearing Rag1 2/2 mice received 5 3 10 6 T cells with or without 5 3 10 6 B cells (98% pure) from wild-type or Tgfbr2 DB mice. Purity was analysed on a Beckman Coulter Cyan ADP flow cytometer and was always .98%. Absolute numbers of particular immune cells in spleen were calculated by multiplying the CD45 1 cell number from one spleen by the percentages of the particular cell type amongst CD45 1 cells. Absolute numbers of particular immune cells (for example, CD8 1 cells) in tumours were calculated by multiplying the cell number in one tumour portion by the percentages of the corresponding cell type in vital tumour cells divided by the weight of the analysed tumour fragment. Subcutaneous tumour models. Two million Myc-Cap 5 or 3 3 10 6 TRAMP-C2 (ref. 17 ) cells (purchased from ATCC) were subcutaneously injected into the right flank. Tumours were measured every 2-3 days using a caliper. Tumour volumes were calculated as width 2 3 length/2. Immune-mediated B cell depletion. B cells were depleted as previously described 38 . Mice were weekly injected (intraperitoneally) with a mixture of monoclonal antibodies, each at 150 mg per mouse: rat anti-mouse CD19 (clone 1D3), rat anti-mouse B220 (clone RA36B2), and mouse anti-mouse CD22 (clone CY34). After 48 h, the mice were injected with a secondary antibody (mouse anti-rat k chain; GeneTex) at 150 mg per mouse. In addition, mice were injected weekly, but not on the same day, with 250 mg per mouse rat anti-mouse CD20 (Genentech). Rat anti-mouse IgG2a and IgG1 were used as isotype controls. Mice were treated for 3 weeks in total ( Fig. 1f and Extended Data Fig. 2j-p) . Oncomine data analysis. In silico analysis of human IgA (IGHA1) mRNA expression was performed using 15 PC microarray gene data sets 14,39-52 from the Oncomine database (Compendia Biosciences; http://www.oncomine.org) 53 comparing a combined 126 carcinoma/adenocarcinoma specimens to 30 normal (either benign, disease-free normal and/or normal adjacent) tissue specimens. Evaluation criteria were set as P , 0.05, fold change .2.0, and gene rank in the top 10%. Analysis of human specimens. Paraffin-embedded specimens from a total of 110 PC patients were integrated into a tissue microarray system (TMA) constructed at the Clinical Institute of Pathology at the Medical University of Vienna (MUV). All of the human specimens used for TMA construction were approved by the MUV Research Ethics Committee (1753/2014). The cohort included 87 patients with E-PC, 9 patients with TR-PC, and 15 patients with M-PC. Patients' demographic and histopathological features are shown in Supplementary Table 2. TMA were designed to provide two cores of normal prostate tissue and four cores of PC tissue from each E-PC patient, and 3-6 cores of tumour tissue for each TR-PC and M-PC patient. Stained TMA slides were digitalized by virtual microscopy at 203 magnification with a fixed light intensity and resolution into a bright-field image using the Nanozoomer (Hamamatsu) scanner. Computerassisted image analysis of individual TMA core images was used to quantify the percentage of CD8 1 and CD20 1 immune reactive area (IRA%) as a proportion of the total digitized haematoxylin-stained region, as previously described 54 . For each PC patient, the mean continuous values of CD8 1 and CD20 1 IRA% in TMA cores without technical artefact for normal and tumour prostate tissue were calculated and used for subsequent statistical analysis. The presence of CD138 1 and IgA 1 double immunoreactivity for plasma cells in the stromal compartment or directly contacting a cancer cell was semiquantitatively scored in TMA cores for each patient by an investigator who was blinded to the patients' tumour features. A value of 0 was assigned to tissue cores without evidence of stromal CD138 1 /IgA 1 double immunoreactive cells and a value of 1 was recorded when CD138 1 /IgA 1 double immunoreactive cells were present in the stromal compartment. Furthermore, after approval from the UCSD Institutional Review Board, whole tissue slides were subjected to immunohistochemical (IHC) analysis of aSMA 1 / IgA, CD8 1 /IgA and IL-10 1 /IgA double staining from a cohort of formalin-fixed, paraffin-embedded radical prostatectomy specimens. As previously described 55 , this cohort included up to 50 patients, which were selected based on known clinical LETTER RESEARCH outcome according to risk categories of low-, intermediate-and high-risk groups based on the D'Amico risk classification 56 .
Anonymized fresh prostatectomy and blood samples from consented human subjects, and de-identified clinical information were provided under the UCSD Moores Cancer Center Biorepository and Tissue Technology Institutional Review Board approved protocol and provided to investigators (M.K., C.J.K., C.A.M.J. and D.E.H.) with Cancer Sample Banking Committee approval. Fresh, de-identified samples of human prostate tissue and blood in 10-ml EDTA-coated tubes were collected from patients undergoing radical prostatectomy for clinically localized, intermediate or high risk PC, Gleason grade 314 or higher. A board-certified genitourinary pathologist (D.E.H.) collected samples of fresh prostate tumour and adjacent benign tissue, within 1 h of radical prostatectomy, that were 5-10 mm in diameter.
Immunostaining. Tissues were embedded in Tissue Tek OCT (Sakura Finetek) compound and snap-frozen. Tissue sections were fixed in cold acetone/methanol or 3% paraformaldehyde for 3-10 min and washed with PBS. Slides were blocked with PBS/1% normal donkey or goat serum for surface staining or 0.2% gelatin (from cold-water fish skin; Sigma-Aldrich)/PBS/1% normal donkey or goat serum for intracellular staining for 30 min. Sections were incubated with primary antibodies for 1 or 12 h at room temperature or 4 uC, respectively. After washing with PBS, secondary antibodies were added for 1 h at room temperature. As negative controls, samples were incubated with isotype-matched control antibodies or secondary antibodies only. After staining with DAPI, sections were covered with Vectashield Mounting Medium (Vector Laboratories). TMA tissue slides from formalin-processed and paraffin-embedded tumour sections were processed for immunohistochemistry. After de-paraffinization and rehydration, sections were immersed in a pre-heated antigen retrieval water bath with a pH 6.1 citrate buffer, or Dako Target Retrieval Solution for 20 min at 95-96 uC. ImmPRESS Polymer System Diaminobenzidine tetrahydrochloride (DAB) peroxidase substrate-based chromogens were used for single staining of CD8, CD20 and for IgA staining when combined with CD138 and for aSMA staining when combined with IgA for IHC of human samples. ImmPACT Vector NovaRED peroxidase substrate-based chromogens were used for CD138 staining when combined with IgA for IHC of human samples. ImmPACT Vector Red Alkanine Phosphatase substrate-based chromogens were used for IgA staining when combined with aSMA for IHC of human samples. All stainings were done according to the manufacturer's protocols (Vector Laboratories). Nuclei were lightly counterstained with a freshly made haematoxylin solution then further washed in water and mounted. Sections were examined using an Axioplan 200 microscope with AxioVision Release 4.5 software (Zeiss) or TCS SPE Leica confocal microscope (Leica). Antibodies. Antibodies specific for the following antigens were used: monoclonal rabbit antibody to cleaved caspase 3 (9661) or p-cH2AX (Ser139; 20E3) (Cell Signaling Technology); polyclonal rabbit antibody to: CD3 (Dako, IS503); aSMA (Dako); Tim-3 (B8.2C12); Tim-1 (RMT1-4); p-SMAD2/3 (D27F4); LC3B (D11) and CD138 (syndecan-1) (anti-mouse Biolegend,; anti-human Dako Ml15); IgA (mA-6E1, m11-44-2, mRMA-1, anti-mouse eBioscience/ Biolegend; anti-human for IHC: Dako, A0262; for FACS: Miltenyi); AID (MAID-2); CD8a (m53-6.7, human DAKO, C8/144B); CD45 (hOKT4); CD20 (AISB12, hL26); CD44 (IM7); CD4(RM4-5); B220 (RA3-6B2); CD19 (m1D3, hHIB19); IgM (II/41); IgD (11-26c); TNF (MP6-XT22); IFNc (XMG1.2); GrzB (NGZB); CD107a (eBio1D48); PD-1 (J43); PD-L1 (MIH5); FAS-L1 (MFL3); Ki67 (SolA15); IgG2a (m2a-15F8); IgG1 (M1-14D12); IL-10 (mJES5-16E3; hJES3-9D7: IHC: hIL-10: AF-217-NA); CD69 (H1.2F3); FoxP3 (FJK/16 s); CD11c (N418); CD11b (M1/70); MHCII (M5/114.15.2); Gr-1 (1A8-l66g); F4/80 (BM8) and NK1.1 (NKR.P1C) (all from eBioscience); CD31 (PECAM-1, MEC 13.3); CD45 (m30-F11); p-STAT1 (pY701) and p-STAT3 (pY705) (BD Bioscience): and aSMA (anti-mouse ab5694; anti-human: DAKO, 1A4). The following Alexa 594-, Alexa 647-, Alexa 488-conjugated secondary antibodies were used: donkey anti-rat IgG, donkey anti-rabbit IgG, donkey anti-goat IgG and goat anti-rat IgG (Molecular Probes, Invitrogen). ELISA. Anti-SV40 Tag immunoglobulin ELISA was performed as described 57 . IgA and IgG ELISA kits were purchased from eBioscience, and used according to manufacturer's protocols. Tumoral single cell suspension has been prepared as described above in the flow cytometry section, and was washed 2-3 times with PBS/2 mM EDTA/2% FCS, to remove soluble IgA. Thereafter, about 3 3 10 6 cells/ 24-well were plated in either 10% FCS/DMEM or Hybridoma medium (Life Technology). After 24 h, the supernatants were analysed for IgA content. Media without cells were used as controls. Treatment with chemotherapy or antibodies. Oxaliplatin was diluted in 5% dextrose and intraperiotenally injected weekly at 6 mg kg 21 as indicated. Anti-PD-L1 antibody was intravenously injected at 10 mg kg 21 once, followed by 5 mg kg 21 bi-weekly. Mice were treated for three weeks for a total of 7 doses per animal.
qRT-PCR analysis. Total RNA was extracted using an RNeasy Plus kit (Qiagen). RNA was reverse transcribed using an IScript kit (Biorad). qRT-PCR was performed using Ssofast EvaGreen supermix (Biorad) on a Biorad CFX96 machine. Primer sequences are listed below and generally were obtained from the NIH qPrimerDepot (http://mouseprimerdepot.nci.nih.gov). The relative expression levels of target genes were measured in triplicates and normalized against the level of RPL32 expression. Fold-difference (as relative mRNA expression) was calculated by the comparative C t method (2 (Ct(RPL32 2 gene of interest)) ). The following primers were used: Ifng, forward 59-TGAACGCTACACACTGCATCT-39, Statistical analysis. Data are presented either mean 6 s.e.m. or median of continuous values and were analysed by Student's t-test or Mann-Whitney U test, respectively, for comparison of two groups. Kruskal-Wallis test was used to compare three or more groups. The log-rank (Mantel-Cox) test was used to compare survival curves. Fisher's exact chi-square P values were used to calculate statistical significance of categorical values between groups. Two-tailed P values of # 0.05 were considered significant. Unpaired t-test-independent studies were used to determine the minimum sample sizes (StatsDirect Version 2.8.0). GraphPad PRISM software was used for statistical analyses. No statistical methods were used to predetermine sample size. The experiments were not randomized. Mouse treatment studies were matched design control trials (see 'Animal models'). 
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Extended Data Figure 1 | Treatment schemes and characterization of tumours and mouse survival before and after treatment. a, Early and late treatment schemes for TRAMP mice. b, TRAMP mice (n 5 3-6 per group) were subjected to early oxaliplatin treatment as described in a and prostate weights were determined at 14 weeks, 1 week after completion of four treatment cycles. Dashed red line indicates prostate weight of tumour-free controls (n 5 33 in total). Prostate weight in b is shown in a log 2 scale. c, d, Histopathology of TRAMP tumours. c, Representative images of haematoxylin-and-eosin-stained prostate sections from TRAMP mice are shown. Scale bars, 100 mm. PD, poorly differentiated adenocarcinoma; PIN, prostatic intraepithelial neoplasia; WD, well differentiated adenocarcinoma. d, Histopathological assessment of early and late treated TRAMP tumours in wild-type and Jh 2/2 mice without or with oxaliplatin treatment. The percentages of the different histotypes shown in c are depicted (n 5 3-7 per group). Fisher's chi-square analysis was used to calculate statistical significance. e, Early and late treatment schemes for mice bearing subcutaneous (s.c.) MC tumours. f, MC cells were subcutaneously transplanted into wild-type and Jh 2/2 mice (n 5 3-7 per group) that were subjected to early oxaliplatin treatment when tumour volume was 100 mm 3 . Forty-eight hours after completion of three treatment cycles, mice were euthanized and tumour volumes (mm 3 ) were measured (n 5 19 in total). g, MC tumours from indicated mice were stained for CD45 (green) and cleaved caspase 3 (CC3; red) (n 5 4-6 per group). h, i, MC tumours (n 5 3-5 per group) grown in wild-type, Jh 2/2 and Cd8a 2/2 mice were stained for CD45 (green) and cH2AX (red), and the cH2AX 1 foci in CD45 2 cells were enumerated (i). Scale bars, 100 mm. All results are mean 6 s.e.m. j, Representative images of subcutaneous MC tumours (n 5 5-6 per group) from wild-type and Jh 2/2 mice, with or without oxaliplatin treatment stained for aSMA (red) and CD31 (green). k, l, Frequency of aSMA-(k) and CD31-(l) positive cells within tumours from j. Shown are median values 6 s.e.m. *P , 0.05; **P , 0.01; ***P , 0.001 (Mann-Whitney and t-tests). m, TRAMP mice (wild-type, Cd8a 2/2 or Jh 2/2 ; n 5 6-14 per group) were treated weekly with low-dose oxaliplatin. Moribund mice were euthanized, and survival was compared by Kaplan-Meyer analysis and significance was determined (wild-type: P . 0.05; Cd8a 2/2 : P . 0.05; Jh 2/2 : **P , 0.002). n, Survival curves for the different TRAMP groups before and after oxaliplatin treatment. Significant differences in survival times are indicated on the right. No statistically significant differences in survival were found between wild-type and Jh 2/2 or Jh 2/2 and Cd8a 2/2 mice without treatment. Significant differences in survival times were observed between all three oxaliplatin-treated groups (wild-type, Cd8a 2/2 or Jh 2/2 ; indicated on the right). *P , 0.05; **P , 0.01; ***P , 0.001 (Kaplan-Meyer analysis). The number of mice used in each experiment and the number of experiments (replications) are shown also in Supplementary Table 1 .
Extended Data Figure 2 T effector cells (CD8 1 CD44 1 cells) in spleen (h) and MC tumours (i) as indicated with or without oxaliplatin treatment. Shown are percentages of the corresponding CD8 1 T cells in the CD8 1 CD44 1 population (n 5 3-5 per group). j, The experimental scheme for B cell immunodepletion in tumourbearing mice. MC tumours were raised in wild-type or Cd8a 2/2 mice, 16 days after subcutaneous tumour cell inoculation. B cells were depleted by twice weekly administration of antibodies directed against CD19, CD20, CD22 and B220. Four days after first antibody treatment, mice were treated with oxaliplatin (n 5 4-7 mice per group, total: 44). After three weekly chemotherapy cycles, mice were euthanized. k, Flow cytometry analysis of tumour-infiltrating CD45 1 CD8 1 T cells stained for IFNc (left) or IFNc and TNF (right) after in vitro restimulation with PMA and ionomycin (n 5 4-6 mice per group). l-n, Flow cytometry analysis of CD19 1 (l, m) and IgA 1 (n) cells in spleens and tumours isolated from the wild-type mice described above, confirming depletion of CD19 1 B cells and oxaliplatin-induced IgA 1 cells in spleen and tumours. o, Serum IgA concentrations in the mice described in j (n 5 3-5 per group). p, Flow cytometry analyses of CD19 1 B cells in tumours isolated from Cd8a 2/2 mice subjected to B cell depletion or not, confirmed the efficient depletion of tumoral CD19 1 B cells. All results are mean 6 s.e.m. *P , 0.05; **P , 0.01; ***P , 0.001 (Mann-Whitney and t-tests).
Extended Data Figure 3 | Immunogenic chemotherapy induces tumour infiltration by immunosuppressive CD19 1 CD20 low B220 low IgA 1 B cells. a, b, MC tumours (n 5 4-9 per group) raised in wild-type mice without or with oxaliplatin treatment were stained for B220 (a), and tumour-infiltrating B220 1 cells per HMF were enumerated (b). In a, single B220 staining (above) and combined staining B220/DAPI (below) are shown. Scale bars, 100 mm. c, d, The flow cytometry plots and gating strategy for analysis of splenic B cell populations using CD19, IgA, B220, CD138 and CD20 antibodies. Results from wild-type mice bearing MC tumours are shown in c and from oxaliplatintreated mice in d (n 5 8 mice per group). Oxaliplatin treatment modestly increased the amount of splenic IgA 1 cells. Splenic IgA 1 cells expressed CD138 as expected and showed lower levels of B220 and CD20, in either control or oxaliplatin-treated mice. e, The gating strategies for analysis of tumoral B cells using CD19, IgA, B220 and CD138 antibodies. Results from MC tumours in two representative oxaliplatin-treated wild-type mice are shown (n 5 8 mice per group), demonstrating the presence of IgA 1 cells in oxaliplatin-treated tumours with a typical CD138 1 B220 low phenotype. f-i, Flow cytometry plots and gating strategies for analysis of tumoral B cell populations using CD19, B220, CD138, IgA and PD-L1 antibodies. 
Extended
RESEARCH LETTER
Extended Data Figure 6 | Analyses of B and T cells in human prostate cancer specimens. a-g, Tissue microarrays of tumour and non-tumour tissue from 110 PC patients were stained for CD8 and CD20 (5-6 spots per patient 5 3-4 tumour tissue and 2 non-tumour tissue). a, b, Representative examples of CD8 (a) and CD20 (b) IHC of PC tissue microarrays (left). Right, computer assisted image analysis with ad hoc developed image software. Tumour tissue is represented in yellow and CD8 1 and CD20 1 cells are represented in red. The percentages of immune reactive area (IRA) occupied by CD8 1 or CD20 1 cells are shown. Scale bars, 200 mm. c, d, Comparison of CD8 and CD20 IRAs in matched non-tumour and tumour tissues from each E-PC patient (n 5 87). e-g, Patients were divided into three subgroups: E-PC (n 5 86), TR-PC (n 5 9) and M-PC (n 5 15). e, CD8 1 cell infiltration into tumour tissues of the different groups. f, CD20 1 cell infiltration into tumour tissues of the different groups. g, The CD8 1 /CD20 1 ratio for the different groups. Each dot represents one patient. Line indicates the median value. Mann-Whitney test was used to calculate statistical significance between the two groups. Kruskal-Wallis test was used to calculate statistical significance between the three groups. h, IHC analysis of low-risk (n 5 5) and high-risk (n 5 5) human PC specimens using IgA (red) and aSMA (black). Nuclei were counterstained with haematoxylin. Scale bar, 100 mm i, Immunofluorescence analysis of human PC showing IL-10expressing (red) IgA 1 (green) CD138 1 (turquoise) plasma cells (n 5 6). Representative images are shown. White arrow indicates IL-10-expressing IgA 1 cells. Scale bars, 50 mm. j, Human normal prostate (n 5 3-5) and human PC (n 5 5) were stained for IgA and CD8. Typical images are shown. Red and green arrows indicate IgA 1 and CD8 1 cells, respectively. Scale bar, 100 mm. k, Human normal prostate (n 5 3) and human PC (n 5 5) were stained for IgA (red arrow) and CD20 (green arrow). Scale bar, 100 mm. l, Flow cytometric analysis of human prostate tumour-infiltrating CD19 1 cells and IgA 1 cells. The percentages of IL-10-expressing B cells in CD19 1 IgA 1 (two different samples) and CD19 1 IgA 2 B cells are shown. m, Summary of results obtained from human blood samples taken from healthy donors (n 5 3) and patients with PC (n 5 5) and prostate tissue specimens (benign, malignant; n 5 4) analysed by flow cytometry for IL-10 expression in CD19 1 IgA 2 and CD19 1 IgA 1 B cells. n, o, Tissue microarrays from 110 patients with PC (described above) were stained for IgA and CD138. Patients were divided into three subgroups: E-PC (n 5 86), TR-PC (n 5 9) and M-PC (n 5 15). n, Representative images of IgA (immunoperoxidase) and CD138 (alkaline phosphatase) double staining of tumour tissues from each group. CD138 1 and IgA 1 double-positive cells in the PC stroma are indicated by the white arrows (haematoxylin counterstain). Scale bar, 100 mm. o, Frequencies of IgA 1 and CD138 1 double-positive cells in the tumour stroma of the different PC patient groups. p, PC patient specimens were divided into two groups: IgA 2/low (n 5 64) and IgA 1/hi (n 5 46). Shown is the CD8 1 /CD20 1 ratio for each group. Each dot represents one patient. Line indicates the median value. q, IgA mRNA expression (IGHA1) is significantly increased in human PC tissue relative to healthy or benign prostate tissue in 5 out of 15 studies evaluated via Oncomine. Results from one significant study 14 are presented. *P , 0.05; **P , 0.01; ***P , 0.001 (chi-square test and Fisher's exact test).
Extended Data Figure 8 | Low-dose cisplatin treatment is devoid of immunogenic activity and low-dose oxaliplatin does not affect gut barrier function. a, Flow cytometry of MC cells stained with annexin V and propidium iodide 24 h after treatment with either oxaliplatin or cisplatin (both at 20 mM). b, Flow cytometry analysis of MC cells treated as above and stained with antibody to the autophagy marker LC3A. c-e, MC tumours were raised in wildtype and Jh 2/2 mice until 400 mm 3 in size, after which the mice were treated with either cisplatin or oxaliplatin at 6 mg kg 21 (n 5 4-5 per group). After three weekly chemotherapy cycles, mice were euthanized. c, Tumour weights; left: wild-type mice; right: Jh 2/2 mice. d, e, Flow cytometry of tumour-infiltrating CD8 (d) and CD4 (e) cells. Left: wild-type mice, right: Jh 2/2 mice. f, Gut permeability was measured in wild-type mice before and after low-(LD) and high-(HD) dose oxaliplatin treatment using orally administered fluorescein isothiocyanate (FITC)-dextran. Shown are FITC-dextran concentrations in serum (mg ml 21 ) (n 5 5 mice per group). g, Serum IgA concentrations in naive wild-type (FVB) and Tgfbr2 DB mice before and after oxaliplatin treatment (n = 3-6 per group). h, IgA staining of colon sections of untreated or low-dose oxaliplatin-treated wild-type mice. Scale bars, 100 mm. i-k, Flow cytometry of CD8 1 (i), CD4 1 (j) and Nk1.1 1 (k) cells in spleens of naive wild-type and Tgfbr2 D mice without or with oxaliplatin treatment. All results are mean 6 s.e.m. *P , 0.05; **P , 0.01; ***P , 0.001 (Mann-Whitney and t-tests).
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